Migraine, Allergy, and Histamine: Is There a Link?

Abstract

The relationship between migraines and allergies is controversial. Though they are epidemiologically linked, the underlying pathophysiological connection between them remains unclear. Migraines and allergic disorders have various underlying genetic and biological causes. As per the literature, these conditions are epidemiologically linked, and some common pathophysiological pathways have been hypothesized. The histaminergic system may be the clue to understanding the correlation among these diseases. As a neurotransmitter in the central nervous system with a vasodilatory effect, histamine has a well-documented influence on the allergic response and could be involved in the pathophysiology of migraines. Histamine may influence hypothalamic activity, which may play a major role in migraines or may simply influence their severity. In both cases, antihistamine drugs could prove useful. This review examines whether the histaminergic system, particularly H3 and H4 receptors, may provide a mechanistic link between the pathophysiology of migraines and allergic disorders, two common and debilitating conditions. Identifying their connection could help identify novel therapeutic strategies.

1. Introduction

Allergists and neurologists regularly receive patients, both pediatric and adult, who suffer from migraines and allergic disorders. However, it is still unclear whether the two disorders are closely related, whether they are triggered by common factors but arise independently, or whether they occur as comorbidities [1].

Migraines and allergic disorders are among the most prevalent disorders worldwide [2,3,4,5,6,7,8,9,10]. Therefore, they can occur in the same patient as comorbidities without being directly related. Their prevalence is 15.2% [11,12] and up to 50% [13] for migraine and allergic rhinitis (AR), respectively. No data are currently available on the overall prevalence of allergic disorders (including AR, rhinosinusitis, rhino-conjunctivitis, asthma, atopic dermatitis, eczema, and food allergy). However, the overall prevalence appears to have been increasing over the last few decades [14,15]. In addition, there are no data on the prevalence of atopy, characterized by an excessive immunoglobulin E (IgE) reaction after exposure to allergic triggers in genetically predisposed individuals [16]. Despite their high prevalence, the two disorders have a bidirectional epidemiological relationship, as several population-based studies have shown [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43]. The proportion of patients in which the two diagnoses overlap is not well investigated [29,37,38]. In addition, allergists, otolaryngologists, and neurologists often have patients reporting “sinus headaches”, which is a common, though nonspecific, diagnosis that should be considered an archaic definition [44,45]. Several studies have confirmed that at least 50% of the patients complaining of sinus headaches meet the international criteria for a migraine diagnosis [46,47,48,49]. Although an epidemiological overlap between the two disorders has been identified, the exact link remains unclear. One possible link is that both diseases have a pathophysiological mechanism based on inflammation and immune dysfunction. It is known that atopy, inflammatory mediators, and elevated neuropeptide mediators all contribute to migraines and allergic disorders such as asthma [50,51,52,53,54]. The histaminergic system could also indicate a link between these diseases. A role of histamine in the etiopathogenesis of migraines has been hypothesized due to its modulation of hypothalamic functions [55]. Knowledge of the histaminergic system could improve the diagnostic process and treatment [56,57]. An in-depth understanding of the role of the histaminergic system in the pathogenesis of the two diseases could help identify more effective therapies and ultimately improve the quality of life of patients affected by both disorders. The objective of the present review is to investigate the epidemiological association between migraines and allergic disorders, focusing on their shared biochemical pathways and underlying mechanisms. The hypothesis that histamine and the histaminergic system play a common role in the pathogenesis of both disorders is discussed, as are the potential therapeutic implications.

2. Materials and Methods

Electronic databases such as PubMed, Scopus, and Web of Science were searched to investigate the relationship/comorbidity of migraine headaches in subjects with allergic/atopic disorders and vice versa from 2000, as well as studies reporting the role of histamine and the histaminergic system in both these conditions and the role of antihistamine drugs from 1960, using the search terms “headache” and “migraine” with the following prefixes: “allergic disorders”, “atopic disorders”, “allergic rhinitis”, “rhinosinusitis”, “rhino-conjunctivitis”, “asthma”, “atopic dermatitis”, “eczema”, “physiopathology”, “histamine”, “histaminergic system”, and “antihistamine drugs”. Moreover, the reference lists of the articles considered were screened to identify additional publications and cases that satisfied the search criteria. In this review, case series or case reports, observational studies (prospective and retrospective cohorts, case–control, and cross-sectional), original research studies, and pooled analyses of original data were included, while other article types, such as commentaries, letters to the editor, and non-English articles, were excluded. Using a data collection form, the following information was extracted: the first author’s name, publication year, study design, sample size, demographic characteristics such as age and sex, country of the population studied, criteria for enrollment, ascertainments for allergic disorders, and definitions of migraine. Two authors (A.F. and M.G.) extracted the data of interest from the studies.

3. Associations between Migraines and Allergic Disorders: Evidence from Population-Based Studies

In the past, the relationship between migraines and allergic/atopic disorders has been a focus of interest [58], even though the reports appear to be conflicting. Population-based studies with large samples and different age groups and countries have been conducted to clarify the epidemiological bidirectional relationship between these disorders [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,59,60]. The main aim of these was to verify a greater comorbidity of allergic disorders in patients suffering from migraines and vice versa. Other aims were to identify whether allergic disorders are correlated with different types of headaches [20,29], whether family allergy and atopy are negative predictors of migraines [21,38], and whether allergy/atopy severity is correlated with the severity of the migraine attack or its recurrence and vice versa [25,29,34,39,41]. Table 1 summarizes the main results of the prospective and retrospective population-based studies conducted since 2000.

As shown in Table 1, most studies reported that allergic/atopic disorders (including allergic rhinitis and atopic dermatitis), asthma, and migraine are reciprocally significantly associated [17,18,19,20,21,22,23,24,25,26,27]. The overlap between allergic disorders without asthma [37,38,39] and atopic dermatitis/eczema [40,41,42,43] with migraine is also consolidated. Among the allergic disorders, the prevalence of asthma in migraine patients and migraines in asthma patients has been investigated the most, and the two conditions have been found to be epidemiologically associated [28,29,30,31,32,33,34,35,36], except in two retrospective studies [59,60]. In two questionnaire-based cross-sectional surveys, Ronchetti et al. found that headaches were not significantly associated with asthma [59]. Becker et al. observed that the risk of developing asthma was not considerably increased for patients with a general practitioner-recorded migraine diagnosis [60]. Beyond the epidemiological overlap between these conditions, studies have identified other linkages: (1) Among the different types of headaches, migraines are more closely correlated with allergic disorders than tension-type headaches [20,22], and migraines with aura are more closely related to allergic disorders than migraines without aura [20]. (2) A family history of migraines may lead to comorbidity with allergy [38], whereas allergy, migraine, and a parental history of asthma were found to be independent risk factors for the presence of migraine in asthmatics. (3) Allergy/atopy and asthma severity are correlated with the severity and frequency of migraine attacks [29], with the highest risk among asthmatic patients with the greatest number of respiratory symptoms [34]. Lower “degrees of atopy” were associated with less frequent and disabling migraines in younger people, while higher degrees were associated with more frequent migraines in patients with allergic rhinitis; in this regard, the administration of immunotherapy is associated with a decreased prevalence and frequency of and disability arising from migraines in younger people [39]. In addition, severe allergic skin symptoms, such as eczema, accompanied by atopy, fatigue, and sleep disturbances increase the severity of headaches [41]. (4) Childhood allergic diseases, such as asthma, atopic dermatitis, allergic conjunctivitis, and rhinitis [24,26], were found to be associated with migraine headaches in adolescence. In addition to population-based studies, several systematic reviews and meta-analyses (not included in Table 1) have confirmed an association between asthma and migraine [61,62,63]. In a systematic review involving 389,573 participants performed to assess the overlapping risk of migraines in asthma patients and vice versa, the odds ratio (OR) of migraines in asthma patients compared with non-asthmatic individuals was found to be 1.62 (95% CI: 1.43–1.82) and migraines were associated with a significantly increased risk of asthma (relative risk (RR): 1.56; 95% CI: 1.51–1.60; p < 0.00001) [61]. A meta-analysis of 15 published population-based studies covering a total of 1,188,780 individuals showed that migraines were associated with increased odds (OR = 1.54; 95% CI: 1.34~1.77) and risk of asthma (HR = 1.42; 95% CI: 1.26~1.60) and asthma was associated with increased odds (OR = 1.45; 95% CI: 1.22~1.72) and risk of migraines (HR = 1.47; 95% CI: 1.41~1.52) [63]. In a systematic review and meta-analysis of observational studies, including seven studies with a total of 549,534 individuals, to determine the association between asthma and migraine, asthma was also associated with increased odds (OR = 1.85; 95% CI: 1.39–2.45) and risk of migraines (RR = 1.70; 95% CI: 1.52–1.90) [62]. However, the same authors concluded that evidence associating asthma and migraine is limited [62]. Population-based studies and derived meta-analyses identify a strong association between migraines and allergic disorders; however, these data are not supported by incontrovertible etiopathogenetic links.

4. Hypothesis of a Common Pathophysiological Pathway

Researchers widely discuss migraines and allergic disorders due to their complex mechanisms that lead to injuries and comorbidities and because they could share common pathophysiological pathways. Some of the most developed theories are listed below.

4.1. Immunological Involvement

Several data support an underlying immunological imbalance in both disorders [20,64]. Serum IgG antibodies to 108 common foods were significantly higher in migraineurs than in the control group [65]. The elimination diet significantly reduced the number of headache days and attacks [65,66]. Despite such evidence, the concept of IgG-mediated food allergy and migraines is considered highly controversial [67]. Duodenal biopsy studies do not support a food allergy–migraine association [68]. Serum IgE and histamine levels were significantly higher in migraineurs than in controls, and all migraine patients had significantly higher histamine levels during headaches than during their non-headache intervals [56]. A meta-analysis also reported elevated IgE levels in people with atopic migraine; however, this was not found in those without allergy [53]. The authors found decreased lymphocyte phagocytic function between migraine attacks [53]. However, the same authors concluded that there was no evidence of immune suppression in migraineurs [53].

4.2. Environmental Factors and Other Triggers

Both disorders are explained by the interaction of genetic and environmental factors [69,70]. Some environmental triggers, such as weather changes and seasonal variation, foods, exercise, and emotional stress, may trigger both allergic disorders and migraines [47,70,71,72,73]. The Saharan dust with the atmospheric airstream, already associated with asthma and allergic rhinitis [74], has been documented to be able to trigger headaches in rats, inducing c-fos expression in nociceptive neurons within trigeminal nucleus caudalis [75]. Sleep pattern changes may also trigger migraines [76]. In this regard, some allergic disorders, such as atopic dermatitis and eczema, may be responsible for sleep disturbances, increasing the frequency and severity of migraine attacks [22,63,77,78,79]. Increased nasal congestion due to seasonal allergies, in addition to altering the quality of sleep, can irritate the trigeminal nerve in the nose, which could trigger a migraine attack. Nasal congestion and rhinorrhea during a migraine attack were reported based on objective endoscopic evidence [77].

4.3. Involvement of Vasoactive Mediators

Studies in adults suggest that primary headaches could be the first sign of atherosclerosis and platelet aggregation [80,81], and in this regard, P2Y12 platelet inhibitors may have a primary prophylactic role in migraine patients [81]. Platelets are activated during an asthma attack and following an antigen provocation, supporting the hypothesis that platelets may also contribute to the pathogenesis of asthma [82]. Vasoactive intestinal peptide (VIP), a vasoactive mediator, present in the neuroendocrine cells of the airway epithelium, is released along with other neuropeptides and neurotransmitters following exposure to the allergen in asthma [83]. VIP also leads to a marked dilation of cranial arteries; however, it does not trigger migraine attacks in migraineurs, as demonstrated in a randomized controlled trial [84]. These data provide some evidence against a purely vascular origin of migraines, as the authors themselves have commented [84].

4.4. Inflammation

The activation of inflammatory mediators (inflammatory interleukins, visinin-like protein 1, YKL-40, lipocalin-2, and TNF-α) may play a role in the pathogenesis of migraines [50,51,52,53,54]. Allergies cause inflammation, which could increase the frequency of migraines. The relationship between migraine and bronchial hyper-reactivity suggests that inflammation is the underlying mechanism in migraine [85]. Transient receptor potential vanilloid subfamily member 1 (TRPV1), expressed in the membranes of sensory afferent fibers and on the trigeminal nociceptors, has been shown to play a key role in the pathophysiology of both migraines and asthma [78,79]. It can be activated by various chemical substances, such as acids, and by heat. Once activated, TRPV1 releases neuropeptides, causing neurogenic inflammation and exerting a vasodilatory effect, which are crucial factors in the generation of migraines [86]. Similarly, TRPV1 expressed in airway C-fiber afferent neurons can be activated by endogenous activators or inhaled irritants, a phenomenon observed in patients presenting with asthma [87].

4.5. Parasympathetic and Trigeminal Nerve Involvement

Some authors believe that, in patients affected by rhinosinusitis and migraines, there is a “physiologically coordinated” regulation of trigeminal and parasympathetic nerve activity [88]. Asthma and migraines are linked by parasympathetic hyperactivity [89]. An increased cholinergic tone has been suggested to trigger bronchospasm in asthma [90], and acetylcholine released by parasympathetic afferents can directly activate the trigeminal pain pathway or provoke the degranulation of mast cells in meninges between migraine attacks [91]. Furthermore, calcitonin gene-related peptide (CGRP), secreted by trigeminal nerves, and vasoactive intestinal peptide (VIP), secreted by parasympathetic nerves, could be involved in the pathophysiology of migraines and rhinosinusitis [88].

5. Role of the Histaminergic System in Migraines

Studies conducted in recent decades have focused on the role of histamine in the central nervous system (CNS) (regulation of the sleep–wake rhythm, hormonal regulation, and cognitive functions) [92,93]. The effects of neuronal histamine are mediated via G-protein-coupled H1–H4 receptors [94]. H1 and H2 receptors function by modulating vascular permeability [55,95]. H3 and H4 receptors, together with the mast cell system, play a role in nociception [96,97,98,99]. The histaminergic system may play an important role in migraine pathophysiology [56,100], and dietary histamine, similar to other chemical dietary triggers, may play a role in some individuals suffering from migraines [101,102]. The following paragraphs will analyze these aspects.

5.1. Histamine and the Central Nervous System

Previous studies have proved that the continuous intravenous infusion of histamine could elicit a headache [103]. This effect is consistent with the hypothesis of mast cells, immunoglobulin E, histamine, and cytokines [94] playing mediating roles in migraine pathways. Histaminergic fibers are represented in the migraine-related neural structures [100], and several studies have documented higher levels of histamine and IgE in patients suffering from migraines compared with controls [56,104]. Histamine, a diamine linked to gastric secretion, mast cells, and the immune system [94], has an important function as a neurotransmitter in the CNS [92]. Histaminergic neurons originate from the tuberomammillary nucleus (TMN) of the posterior hypothalamus [100], which projects to a suprachiasmatic nucleus (SCN) [105,106] of the hypothalamus itself. The histamine released from the TMN helps to modulate the circadian rhythm, the sleep–wake cycle, pituitary hormone secretion, thermoregulation, energy expenditure, and food intake [94,107]. During wakefulness, its activation is variable; however, during somnolence and sleep, it is no longer activated through gamma-aminobutyric acid connections [108]. The extracellular levels of histamine in the preoptic/anterior hypothalamus follow the oscillations of the different sleep phases (wake > non-REM sleep > REM sleep) [108], providing further evidence of the importance of histamine in circadian regulation [55]. The close correlation between the regulation of circadian rhythms and migraines [109] has also been confirmed through migraine mouse model studies, which have suggested an inadequate coping mechanism compared to that of the general population as a possible cause [110]. The pain response and modulation of headache attacks are other histamine-mediated hypothalamic functions [55,111]. Rat studies have demonstrated strict connections between the TMN, thalamic nuclei, and the trigeminal output, indicating that histamine may trigger headache stressors involved in the perception of whole-body allodynia (abnormal skin sensitivity) and photophobia (abnormal sensitivity to light) during migraine [112,113]. The histaminergic system is also connected with the trigeminal vascular system, known to be involved in migraine pathophysiology [114,115,116], and with orexinergic, noradrenergic, and serotonergic areas [55,92]. For these reasons, it plays a role in a wide range of cognitive functions and acts as a general index of stress [117]. Histamine is released in response to stressors that could elicit or worsen migraine attacks in genetically predisposed individuals [118]. Dietary histamine, similar to other chemical food triggers, might play a role in some individuals suffering from migraines. Some foods and alcoholic beverages that are high in histamine could trigger or worsen migraine attacks in these people due to histamine’s action on the CNS [101,102]. Symptoms may be worse in individuals with histamine intolerance due to impaired histamine degradation based on reduced activity of diamine oxidase, the main enzyme involved in the metabolism of ingested histamine [119,120].

5.2. H1 and H2 Receptors

H1 receptor (H1R) seems to be linked to the control mechanisms of the tight junctions of the BBB. In cultured brain endothelial cells, the histaminergic system increases synaptic activity by modulating glucose intake [121]. When H1R is stimulated, it modulates vascular permeability by inducing the production of nitric oxide (NO) by activating nitric oxide synthase [55]. Studies of glyceryl trinitrate (GTN) and histamine-induced headaches have indicated that NO may initiate migraine attacks [95]. The substances that have been shown to reliably cause more headaches than placebos in single-dose experiments were GTN and histamine, with NO as the common mediator [95]. Histamine 2 receptor (H2R), abundant in the basal ganglia, amygdala, and hippocampus and commonly residing close to H1R [100], also acts in hippocampal long-term potentiation, memory consolidation, and spatial navigation and regulates vascular tone and BBB permeability [100,122]. Finally, H2R plays a role in the expression of vascular protective factors in astrocytes and brain microvascular endothelial cells [123].

5.3. H3 and H4 Receptors

The H3 receptor (H3R) is located presynaptically (in peripheral and CNS) and inhibits neurons, leading to the auto-inhibition of the histaminergic neurons themselves [55]. Some polymorphisms associated with impaired H3R functioning have been associated with a greater risk for the development of some neurological diseases, including migraines [124,125]. These findings can be explained by the anti-nociceptive function of these receptors [96,97,98], a function possibly related to a similar action in the modulation of the release of CGRP and pain substance (SP) through the prejunctional histamine H3R located on the peripheral endings of the sensory nerves [113]. Moreover, histamine has a selective affinity for H3R and may specifically inhibit the neurogenic edema response involved in migraine pathophysiology, modulating the vascular permeability [126,127]. The H4 receptor (H4R) shows considerable homology with the H3R (35%) and is primarily found in peripheral tissues and immune cells [55]. Recently, a functional expression of H4R within neurons of the CNS in the rat lumbar dorsal root ganglia (DRG) and in the lumbar spinal cord [100,128] has been reported [129,130]. H4R modulators may play a role in pain modulation (antinociceptive effect) as well as inflammatory and immune processes, as suggested by animal studies [128,129].

5.4. Mast Cells and Pain Neuromodulation

Mast cells may represent another tight link between the histaminergic system and the modulation of nociception associated with migraines [55,100,131]. The proximity of mast cells to nociceptive nerve endings in many cutaneous and deep tissues, including meninges, suggests a functional neuroimmune interaction involving mast cells and nociceptive neurons [52,132]. Migraine is generally accepted to be mediated by the prolonged activation of meningeal nociceptors [131,133]. In rat studies on meningeal nociceptors, the degranulation of dural mast cells induced a prolonged state of excitation in meningeal nociceptors. Nociceptor interaction was associated with an increased expression of nociception-associated kinases (pERK) and with a downstream activation of the nucleus of the spinal trigeminal, indicated by the increased expression of c-fos [133]. In addition, activated macrophages, microglia, and mast cells in the CNS release pro-inflammatory cytokines, which cause an increase in the arachidonic acid levels, leading to migraines and other neurological manifestations, including fatigue, nausea, and brain fog [134]. Once again, CGRP seems to be one of the molecules most involved, both through vasodilation of the dural blood vessels and through an induced degranulation of the mast cells, resulting in the extravasation of plasma proteins underlying the neurogenic inflammation and pain of migraines [99,131].

6. Role of Anti-Allergic Drugs in Headaches

Several studies have investigated the efficacy of prophylactic pharmacologic and non-pharmacologic therapy in the migraine patient [135,136,137,138]. However, in recent decades, few studies have been conducted to demonstrate the efficacy of antihistamine drugs in managing patients who suffer from migraines [139]. Studies on the H1 and H2 antihistamines have shown contradictory results on the efficacy of these drugs in the prophylaxis of the migraine patient [57,135,140,141,142,143,144,145,146,147,148,149]. Some studies focusing on H3R [126,150,151,152,153] and H4R [129,154,155] have obtained more promising results [129,150,151,152,153,154,155,156]. Table 2 summarizes the antihistamines used for each specific receptor and whether the study conducted was a pre-clinical or clinical trial. The following paragraphs address these topics.

6.1. H1 and H2 Antihistamines

Studies of H1 and H2 antihistamines lack scientific strength and show contrasting results [140]. In a prospective double-blind clinical trial, the combination of nalbuphine (an opioid analgesic known to be effective in migraine) and hydroxyzine was not significantly more effective when compared with treatment groups administered with nalbuphine or hydroxyzine alone or compared with the placebo group [142]. Among H1 antagonists, cinnarizine and cyproheptadine have been reported to be effective in preventing migraines [55]. A significant relief in the frequency, duration, and severity of migraine attacks was recorded when cyproheptadine and propranolol (noncardioselective β blocker used in the prophylaxis of migraine) [158,159] were used independently [158,160] or in combination compared to a placebo [157]. One open-label pilot trial demonstrated a significant reduction in the number of migraine days and the intake of medication to treat acute attacks in patients treated with cinnarizine [143]. This evidence was confirmed by a subsequent open-label trial [57]. When the efficacies of cinnarizine and valproate were tested and compared, a significant decrease in terms of migraine symptoms was confirmed in both groups, although a greater efficacy of valproate was reported (55% vs. 36.4%) [144]. Experience in the adult population has suggested the use of these drugs in the prophylaxis of migraine in the pediatric population [140]: cinnarizine and sodium valproate were safe and effective for the prophylaxis of childhood patients, as indicated by two randomized double-blind placebo-controlled trials [145,146]. It is interesting to note that the chemical structure and the pharmacological profile of cinnarizine are similar to those of flunarizine [161], a “selective” calcium-entry blocker and histamine antagonist H1 receptor [161,162] known for its effectiveness in the prophylactic treatment of migraines in adults and children [163,164]. In contrast, in a study conducted in 1964, cyproheptadine was investigated in comparison with methysergide (a specific serotonin receptor antagonist) [165] and bellergal (a mixture of phenobarbitone, ergotamine tartrate, and belladonna alkaloids) [166], and no evidence of statistical improvement of migraine was demonstrated, with the placebo showing better outcomes [141]. A double-blind randomized placebo-controlled study evaluated the effect of clemastine (another H1 antihistamine) on migraine induction by pituitary adenylate cyclase-activating peptide-38 (PACAP38), albeit unsuccessfully [147]. Similarly, a histamine H2 blocker known as cimetidine, either alone or in combination with an H1 blocker (chlorpheniramine), was demonstrated to be ineffective in several studies [140,148,149]. In conclusion, H1 and H2 blockers have not definitively demonstrated an effective role in the prophylaxis of the migraine patient, and further high-quality randomized placebo-controlled studies in both children and adults are needed to confirm the data [55,140,141,142,143,144,146,157,167,168].

6.2. H3 and H4 Antihistamines

A feedback mechanism of histamine release [130,150,156,169] and the antinociceptive action [96,97,98,128,129,170] could offer a new therapeutic perspective in migraine prophylaxis [55,140]. However, until now, studies on H4R have only been conducted in animal models [129,154,155]. Interesting results have been reported in the studies conducted on n-alpha-methylhistamine [55,140], a histamine catabolite with a selective affinity for H3R [150,171,172]. Administration of a low dose of histamine or its catabolite might stimulate the H3R feedback loop, reducing histamine release [171]. In randomized, double-blind controlled trials, subcutaneous administration has proved the efficacy of n-alpha-methylhistamine in reducing the intensity, frequency, and duration of the headache [126,150,151,152,153]. Due to the inhibition of the neurogenic edema response involved in migraine pathophysiology [156], histaminergic H3R agonists reduce the intake of analgesic drugs in migraine patients [150], which is explained by the inhibition of plasma protein extravasation and the promotion of brain electrical activity, consistent with the different phases of the circadian rhythm [127]. Moreover, the authors proved that a low dose of histamine or subcutaneous n-alpha-methylhistamine has effects similar to, or even greater than, those of sodium valproate [126], topiramate [151], botulinum toxin type A [152], and propranolol [153]. Based on this evidence, other studies have attempted to evaluate the role of H4R (35–40% homology with H3R) [140]. Considering that amitriptyline, a well-known prophylactic drug for migraine [173], has shown affinity for H4R, there are positive expectations from molecules potentially capable of binding this receptor [174]. To clarify the pathophysiological role of this receptor, the H4R agonist “VUF 8430” has been tested in animal models via intracerebroventricular administration [129]. Neuronal H4R activation had an acute thermal analgesic effect, suggesting that H4R might be involved in the production of analgesia in the absence of an inflammatory process [129]. The same result has been achieved with the selective blockade of H4R instead of its agonist [154,155]. This evidence prevents a consensus on the impact of this receptor on migraine pathways. Further description of its localization and function is required [140]. In conclusion, H3 and H4 antihistamines appear promising in migraine prophylaxis [126,140,150,151,152,153,156], even if the actual data are still discordant [129,154,155].

7. Discussion

Migraines and allergic disorders are conditions with a high and increasing prevalence in the general population [12,14]. These conditions are associated with a socioeconomic burden and with a decrease in the quality of life, especially when both disorders coexist in the same individual [16]. Due to their incidence, these disorders may exist in the same patient even though they are not etiopathogenically related. However, several studies have highlighted that the bidirectional association between migraines and allergic disorders could be much more than a coincidence [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,59,60]. In particular, asthma, atopic dermatitis/allergic eczema, and allergic rhinitis are the allergic disorders most frequently reported in children, adolescents, and adults complaining of migraine. Although a clear epidemiological overlap has been established, it is not clear why some allergic disorders are more frequently reported than others. A possible explanation is that asthma, atopic dermatitis, and allergic rhinitis are the disorders most investigated as those associated with the greatest impact on patients’ quality of life and for which patients most often approach allergy doctors. The recurrence of migraine attacks and their severity depend on the interaction between genetic and environmental factors [69]. Any situation of malaise or discomfort can worsen the migraine in an individual who is genetically predisposed to them [76]. In this respect, patients with symptomatic allergic disorders are more likely to have attacks of high frequency and severity. Furthermore, the same environmental factors and emotional stress or psychological distress are associated with the occurrence or worsening of allergic conditions such as asthma and are related to the rate of emergency department attendance for migraine [175,176]. Immunological and vasoactive mediators, inflammation, and the involvement of parasympathetic and trigeminal nerves could play a combined role, which reinforces the common pathogenic link between these conditions. With these premises, it is difficult to exclude the possibility that the higher prevalence of migraines among the allergic population is simply due to a higher incidence of the disease. Although both disorders are frequently comorbid and may share common pathophysiological mediators and pathways, there is still not enough scientific evidence to draw a definitive conclusion regarding whether there is a direct relationship between migraines and allergic disorders. Both disorders undoubtedly remain two distinct conditions, each of which is genetically determined, but share some common pathogenic pathways. As summarized in this review, some evidence supports a role for histamine and the histaminergic system in several pathways associated with the pathophysiological mechanisms of migraines and allergic disorders. As a neurotransmitter of the CNS [92], histamine is involved in various brain activities that are often altered during a migraine, such as the sleep–wake cycle. Furthermore, playing a role in the immune system [94] and being a vasoactive mediator capable of modifying BBB permeability and neurogenic inflammation [127], histamine has been a much-studied therapeutic target in migraine prophylaxis. H1/H2R antagonists have produced contradictory results in the management of migraine patients [141,142,143,144,146,157,167]. For this reason, their use in clinical practice is far from recognized. Promising results have instead been obtained with substances that modulate H3/H4R [126,129,150,151,152,153,154,155,156]; however, many drugs have only been studied in the pre-clinical phase [140]. This study has several limitations: (1) The method of data collection in population-based studies (often through questionnaires or collection of patient data from pre-existing databases) may not have allowed the diagnosis of patients according to international definitions of migraine, asthma, allergic rhinitis, and other conditions. (2) In these studies, detailed information and laboratory data related to allergy, including serum IgE levels, eosinophil levels, allergic tests, and family histories of atopy, were unavailable. (3) Most studies have examined the correlation between migraines and isolated allergic disorders but not a combination of allergic disorders. (4) Basic studies have focused on describing the pathogenic pathways of migraine or allergic disorders, but there are none designed to examine common mechanisms between them. (5) The studies on the efficacy of antihistamine drugs in the prophylaxis of migraine have been conducted on small cohorts, which may limit the generalizability of the results; moreover, the studies have often not been randomized and have lacked comparison or placebo groups.

8. Conclusions

For centuries, clinical and epidemiological studies have recognized the overlap between migraines and allergic disorders. Whether it is a causal relationship is uncertain, and it cannot be excluded that migraines may merely be more recognizable in allergic patients since the malaise due to allergy worsens migraine symptoms. Though migraines and allergic disorders may share some common pathogenic pathways, it is far from clear whether there is a direct relationship between the two conditions. Whichever is the case, this review underlines the importance of considering allergic comorbid disorders among patients suffering from migraines so both conditions can be treated. Regarding future research directions, further studies are needed to gather more information on different aspects of this topic. Additional longitudinal studies in patients of all ages are required to verify the epidemiological overlap between migraines and allergic disorders. From the pathophysiological point of view, basic studies on the possible shared pathways (inflammatory, immunological, etc.) and systems (autonomic, histaminergic, etc.) for the development of new therapeutic strategies, are indicated. From the therapeutic point of view, pre-clinical studies and randomized, placebo-controlled clinical trials are needed to evaluate the preventive role of anti-allergic therapies in the occurrence of migraines in patients suffering from allergic disorders. From a clinical point of view, management of patients with migraines should also include screening for associated allergic symptoms. This could lead to a significant impact on public health due to the early identification and treatment possibilities of patients with comorbidities, improving their quality of life.

References

1. Vaughan W.T.. Allergic Migraine. JAMA. 1927;88 1383. doi:10.1001/jama.1927.02680440017006
2. Bousquet J., Anto J.M., Bachert C., Baiardini I., Bosnic-Anticevich S., Walter Canonica G., et al.. Allergic Rhinitis. Nat. Rev. Dis. Primers. 2020;6 95. doi:10.1038/s41572-020-00227-0
3. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al.. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (in Collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 8–160. doi:10.1111/j.1398-9995.2007.01620.x
4. Wheatley L.M., Togias A.. Clinical Practice. Allergic Rhinitis. N. Engl. J. Med.. 2015;372 456–463. doi:10.1056/NEJMcp1412282
5. Greiner A.N., Hellings P.W., Rotiroti G., Scadding G.K.. Allergic Rhinitis. Lancet. 2011;378 2112–2122. doi:10.1016/S0140-6736(11)60130-X
6. Dierick B.J.H., van der Molen T., Flokstra-de Blok B.M.J., Muraro A., Postma M.J., Kocks J.W.H., et al.. Burden and Socioeconomics of Asthma, Allergic Rhinitis, Atopic Dermatitis and Food Allergy. Expert. Rev. Pharm. Outcomes Res.. 2020;20 437–453. doi:10.1080/14737167.2020.1819793
7. Sultész M., Horváth A., Molnár D., Katona G., Mezei G., Hirschberg A., et al.. Prevalence of Allergic Rhinitis, Related Comorbidities and Risk Factors in Schoolchildren. Allergy Asthma Clin. Immunol.. 2020;16 98. doi:10.1186/s13223-020-00495-1
8. Stovner L., Hagen K., Jensen R., Katsarava Z., Lipton R., Scher A., et al.. The Global Burden of Headache: A Documentation of Headache Prevalence and Disability Worldwide. Cephalalgia. 2007;27 193–210. doi:10.1111/j.1468-2982.2007.01288.x
9. Steiner T.J., Stovner L.J., Vos T.. GBD 2015: Migraine Is the Third Cause of Disability in under 50s. J. Headache Pain. 2016;17 104. doi:10.1186/s10194-016-0699-5
10. GBD 2016 Headache Collaborators Global, Regional, and National Burden of Migraine and Tension-Type Headache, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Neurol.. 2018;17 954–976. doi:10.1016/S1474-4422(18)30322-3
11. GBD 2019 Diseases and Injuries Collaborators Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396 1204–1222. doi:10.1016/S0140-6736(20)30925-9
12. Steiner T.J., Stovner L.J.. Global Epidemiology of Migraine and Its Implications for Public Health and Health Policy. Nat. Rev. Neurol.. 2023;19 109–117. doi:10.1038/s41582-022-00763-1
13. Bousquet P.-J., Leynaert B., Neukirch F., Sunyer J., Janson C.M., Anto J., et al.. Geographical Distribution of Atopic Rhinitis in the European Community Respiratory Health Survey I. Allergy. 2008;63 1301–1309. doi:10.1111/j.1398-9995.2008.01824.x
14. Mahesh P.A., Moitra S., Ulaganathan M., Garg M., Malamardi S., Vedanthan P.K., et al.. Allergic Diseases in India—Prevalence, Risk Factors and Current Challenges. Clin. Exp. Allergy. 2023;53 276–294. doi:10.1111/cea.14239
15. Verlato G., Corsico A., Villani S., Cerveri I., Migliore E., Accordini S., et al.. Is the Prevalence of Adult Asthma and Allergic Rhinitis Still Increasing? Results of an Italian Study. J. Allergy Clin. Immunol.. 2003;111 1232–1238. doi:10.1067/mai.2003.1484
16. Özge A., Uluduz D., Bolay H.. Co-Occurrence of Migraine and Atopy in Children and Adolescents: Myth or a Casual Relationship?. Curr. Opin. Neurol.. 2017;30 287–291. doi:10.1097/WCO.0000000000000439
17. Sillanpää M., Aro H.. Headache in Teenagers: Comorbidity and Prognosis. Funct. Neurol.. 2000;15 116–121.
18. Ozge A., Ozge C., Oztürk C., Kaleagasi H., Ozcan M., Yalçinkaya D.E., et al.. The Relationship between Migraine and Atopic Disorders-the Contribution of Pulmonary Function Tests and Immunological Screening. Cephalalgia. 2006;26 172–179. doi:10.1111/j.1468-2982.2005.01021.x
19. Lateef T.M., Cui L., Nelson K.B., Nakamura E.F., Merikangas K.R.. Physical Comorbidity of Migraine and Other Headaches in US Adolescents. J. Pediatr.. 2012;161 308–313.e1. doi:10.1016/j.jpeds.2012.01.040
20. Özge A., Öksüz N., Ayta S., Uluduz D., Yıldırım V., Toros F., et al.. Atopic Disorders Are More Common in Childhood Migraine and Correlated Headache Phenotype. Pediatr. Int.. 2014;56 868–872. doi:10.1111/ped.12381
21. Turan M.O., Susuz Ç.Ç., Turan P.A.. Presence of Headache and Migraine in Asthma Patients. Turk. Thorac. J.. 2017;18 47–51. doi:10.5152/TurkThoracJ.2017.16008
22. Eidlitz-Markus T., Zolden S., Haimi-Cohen Y., Zeharia A.. Comparison of Comorbidities of Migraine and Tension Headache in a Pediatric Headache Clinic. Cephalalgia. 2017;37 1135–1144. doi:10.1177/0333102416665870
23. Graif Y., Shohat T., Machluf Y., Farkash R., Chaiter Y.. Association between Asthma and Migraine: A Cross-Sectional Study of over 110 000 Adolescents. Clin. Respir. J.. 2018;12 2491–2496. doi:10.1111/crj.12939
24. Wei C.-C., Lin C.-L., Shen T.-C., Chen A.-C.. Children with Allergic Diseases Have an Increased Subsequent Risk of Migraine upon Reaching School Age. J. Investig. Med.. 2018;66 1064–1068. doi:10.1136/jim-2018-000715
25. Buse D.C., Reed M.L., Fanning K.M., Bostic R.C., Lipton R.B.. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2020;60 2340–2356. doi:10.1111/head.13966
26. Manjunath J., Silverberg J.I.. Association between Atopic Dermatitis and Headaches throughout Childhood and Adolescence-A Longitudinal Birth Cohort Study. Pediatr. Dermatol.. 2021;38 780–786. doi:10.1111/pde.14607
27. Han J.H., Lee H.J., Yook H.J., Han K., Lee J.H., Park Y.M.. Atopic Disorders and Their Risks of Migraine: A Nationwide Population-Based Cohort Study. Allergy Asthma Immunol. Res.. 2023;15 55–66. doi:10.4168/aair.2023.15.1.55
28. Davey G., Sedgwick P., Maier W., Visick G., Strachan D.P., Anderson H.R.. Association between Migraine and Asthma: Matched Case-Control Study. Br. J. Gen. Pract.. 2002;52 723–727.
29. Aamodt A.H., Stovner L.J., Langhammer A., Hagen K., Zwart J.-A.. Is Headache Related to Asthma, Hay Fever, and Chronic Bronchitis? The Head-HUNT Study. Headache. 2007;47 204–212. doi:10.1111/j.1526-4610.2006.00597.x
30. Lateef T.M., Merikangas K.R., He J., Kalaydjian A., Khoromi S., Knight E., et al.. Headache in a National Sample of American Children: Prevalence and Comorbidity. J. Child. Neurol.. 2009;24 536–543. doi:10.1177/0883073808327831
31. Fernández-de-Las-Peñas C., Hernández-Barrera V., Carrasco-Garrido P., Alonso-Blanco C., Palacios-Ceña D., Jiménez-Sánchez S., et al.. Population-Based Study of Migraine in Spanish Adults: Relation to Socio-Demographic Factors, Lifestyle and Co-Morbidity with Other Conditions. J. Headache Pain. 2010;11 97–104. doi:10.1007/s10194-009-0176-5
32. Karlstad Ø., Nafstad P., Tverdal A., Skurtveit S., Furu K.. Comorbidities in an Asthma Population 8–29 Years Old: A Study from the Norwegian Prescription Database. Pharmacoepidemiol. Drug. Saf.. 2012;21 1045–1052. doi:10.1002/pds.2233
33. Czerwinski S., Gollero J., Qiu C., Sorensen T.K., Williams M.A.. Migraine-Asthma Comorbidity and Risk of Hypertensive Disorders of Pregnancy. J. Pregnancy. 2012;2012 858097. doi:10.1155/2012/858097
34. Martin V.T., Fanning K.M., Serrano D., Buse D.C., Reed M.L., Lipton R.B.. Asthma Is a Risk Factor for New Onset Chronic Migraine: Results from the American Migraine Prevalence and Prevention Study. Headache. 2016;56 118–131. doi:10.1111/head.12731
35. Peng Y.-H., Chen K.-F., Liao W.-C., Hsia T.-C., Chen H.-J., Yin M.-C., et al.. Association of Migraine with Asthma Risk: A Retrospective Population-Based Cohort Study. Clin. Respir. J.. 2018;12 1030–1037. doi:10.1111/crj.12623
36. Kim S.Y., Min C., Oh D.J., Lim J.-S., Choi H.G.. Bidirectional Association between Asthma and Migraines in Adults: Two Longitudinal Follow-up Studies. Sci. Rep.. 2019;9 18343. doi:10.1038/s41598-019-54972-8
37. Ku M., Silverman B., Prifti N., Ying W., Persaud Y., Schneider A.. Prevalence of Migraine Headaches in Patients with Allergic Rhinitis. Ann. Allergy Asthma Immunol.. 2006;97 226–230. doi:10.1016/S1081-1206(10)60018-X
38. Artto V., Wessman M., Nissilä M., Säkö E., Liukkonen J., Teirmaa H., et al.. Comorbidity in Finnish Migraine Families. J. Headache Pain. 2006;7 324–330. doi:10.1007/s10194-006-0319-x
39. Martin V.T., Taylor F., Gebhardt B., Tomaszewski M., Ellison J.S., Martin G.V., et al.. Allergy and Immunotherapy: Are They Related to Migraine Headache?. Headache. 2011;51 8–20. doi:10.1111/j.1526-4610.2010.01792.x
40. Saunes M., Smidesang I., Holmen T.L., Johnsen R.. Atopic Dermatitis in Adolescent Boys Is Associated with Greater Psychological Morbidity Compared with Girls of the Same Age: The Young-HUNT Study. Br. J. Dermatol.. 2007;156 283–288. doi:10.1111/j.1365-2133.2006.07688.x
41. Silverberg J.I.. Association between Childhood Eczema and Headaches: An Analysis of 19 US Population-Based Studies. J. Allergy Clin. Immunol.. 2016;137 492–499.e5. doi:10.1016/j.jaci.2015.07.020
42. Shreberk-Hassidim R., Hassidim A., Gronovich Y., Dalal A., Molho-Pessach V., Zlotogorski A.. Atopic Dermatitis in Israeli Adolescents from 1998 to 2013: Trends in Time and Association with Migraine. Pediatr. Dermatol.. 2017;34 247–252. doi:10.1111/pde.13084
43. Fan R., Leasure A.C., Damsky W., Cohen J.M.. Migraine among Adults with Atopic Dermatitis: A Cross-Sectional Study in the All of Us Research Programme. Clin. Exp. Dermatol.. 2023;48 24–26. doi:10.1093/ced/llac004
44. Cady R.K., Dodick D.W., Levine H.L., Schreiber C.P., Eross E.J., Setzen M., et al.. Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. Mayo Clin. Proc.. 2005;80 908–916. doi:10.4065/80.7.908
45. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018;38 1–211. doi:10.1177/0333102417738202
46. Schreiber C.P., Hutchinson S., Webster C.J., Ames M., Richardson M.S., Powers C.. Prevalence of Migraine in Patients with a History of Self-Reported or Physician-Diagnosed “Sinus” Headache. Arch. Intern. Med.. 2004;164 1769–1772. doi:10.1001/archinte.164.16.1769
47. Eross E., Dodick D., Eross M.. The Sinus, Allergy and Migraine Study (SAMS). Headache. 2007;47 213–224. doi:10.1111/j.1526-4610.2006.00688.x
48. Perry B.F., Login I.S., Kountakis S.E.. Nonrhinologic Headache in a Tertiary Rhinology Practice. Otolaryngol. Head. Neck Surg.. 2004;130 449–452. doi:10.1016/j.otohns.2004.01.005
49. Mehle M.E., Kremer P.S.. Sinus CT Scan Findings in “Sinus Headache” Migraineurs. Headache. 2008;48 67–71. doi:10.1111/j.1526-4610.2007.00811.x
50. Dündar A., Cafer V., Aslanhan H., Özdemir H.H., Yilmaz A., Çevik M.U.. Increased Visinin-like Protein-1, YKL-40, Lipocalin-2, and IL-23 Levels in Patients with Migraine. Neurol. Res.. 2023;45 97–102. doi:10.1080/01616412.2022.2156125
51. Yilmaz I.A., Ozge A., Erdal M.E., Edgünlü T.G., Cakmak S.E., Yalin O.O.. Cytokine Polymorphism in Patients with Migraine: Some Suggestive Clues of Migraine and Inflammation. Pain Med.. 2010;11 492–497. doi:10.1111/j.1526-4637.2009.00791.x
52. Levy D., Burstein R., Strassman A.M.. Mast Cell Involvement in the Pathophysiology of Migraine Headache: A Hypothesis. Headache. 2006;46 S13–S18. doi:10.1111/j.1526-4610.2006.00485.x
53. Kemper R.H., Meijler W.J., Korf J., Ter Horst G.J.. Migraine and Function of the Immune System: A Meta-Analysis of Clinical Literature Published between 1966 and 1999. Cephalalgia. 2001;21 549–557. doi:10.1046/j.1468-2982.2001.00196.x
54. Mehle M.E.. Migraine and Allergy: A Review and Clinical Update. Curr. Allergy Asthma Rep.. 2012;12 240–245. doi:10.1007/s11882-012-0251-x
55. Alstadhaug K.B.. Histamine in Migraine and Brain. Headache. 2014;54 246–259. doi:10.1111/head.12293
56. Gazerani P., Pourpak Z., Ahmadiani A., Hemmati A., Kazemnejad A.. A Correlation between Migraine, Histamine and Immunoglobulin e. Scand. J. Immunol.. 2003;57 286–290. doi:10.1046/j.1365-3083.2003.01216.x
57. Togha M., Ashrafian H., Tajik P.. Open-Label Trial of Cinnarizine in Migraine Prophylaxis. Headache. 2006;46 498–502. doi:10.1111/j.1526-4610.2006.00381.x
58. Unger A.H., Unger L.. Migraine Is an Allergic Disease. J. Allergy. 1952;23 429–440. doi:10.1016/0021-8707(52)90007-5
59. Ronchetti R., Villa M.P., Matricardi P.M., La Grutta S., Barreto M., Pagani J., et al.. Association of Asthma with Extra-Respiratory Symptoms in Schoolchildren: Two Cross-Sectional Studies 6 Years Apart. Pediatr. Allergy Immunol.. 2002;13 113–118. doi:10.1034/j.1399-3038.2002.01036.x
60. Becker C., Brobert G.P., Almqvist P.M., Johansson S., Jick S.S., Meier C.R.. The Risk of Newly Diagnosed Asthma in Migraineurs with or without Previous Triptan Prescriptions. Headache. 2008;48 606–610. doi:10.1111/j.1526-4610.2007.01030.x
61. Sayyah M., Saki-Malehi A., Javanmardi F., Forouzan A., Shirbandi K., Rahim F.. Which Came First, the Risk of Migraine or the Risk of Asthma? A Systematic Review. Neurol. Neurochir. Pol.. 2018;52 562–569. doi:10.1016/j.pjnns.2018.07.004
62. Kang L.-L., Chen P.-E., Tung T.-H., Chien C.-W.. Association Between Asthma and Migraine: A Systematic Review and Meta-Analysis of Observational Studies. Front. Allergy. 2021;2 741135. doi:10.3389/falgy.2021.741135
63. Wang L., Deng Z.-R., Zu M.-D., Zhang J., Wang Y.. The Comorbid Relationship Between Migraine and Asthma: A Systematic Review and Meta-Analysis of Population-Based Studies. Front. Med.. 2020;7 609528. doi:10.3389/fmed.2020.609528
64. Mortimer M.J., Kay J., Gawkrodger D.J., Jaron A., Barker D.C.. The Prevalence of Headache and Migraine in Atopic Children: An Epidemiological Study in General Practice. Headache. 1993;33 427–431. doi:10.1111/j.1526-4610.1993.hed3308427.x
65. Arroyave Hernández C.M., Echavarría Pinto M., Hernández Montiel H.L.. Food Allergy Mediated by IgG Antibodies Associated with Migraine in Adults. Rev. Alerg. Mex.. 2007;54 162–168.
66. Alpay K., Ertas M., Orhan E.K., Ustay D.K., Lieners C., Baykan B.. Diet Restriction in Migraine, Based on IgG against Foods: A Clinical Double-Blind, Randomised, Cross-over Trial. Cephalalgia. 2010;30 829–837. doi:10.1177/0333102410361404
67. Pascual J., Oterino A.. IgG-Mediated Allergy: A New Mechanism for Migraine Attacks?. Cephalalgia. 2010;30 777–779. doi:10.1177/0333102410364856
68. Pradalier A., de Saint Maur P., Lamy F., Launay J.M.. Immunocyte Enumeration in Duodenal Biopsies of Migraine without Aura Patients with or without Food-Induced Migraine. Cephalalgia. 1994;14 365–367. doi:10.1046/j.1468-2982.1994.1405365.x
69. Grangeon L., Lange K.S., Waliszewska-Prosół M., Onan D., Marschollek K., Wiels W., et al.. Genetics of Migraine: Where Are We Now?. J. Headache Pain. 2023;24 12. doi:10.1186/s10194-023-01547-8
70. Custovic A., de Moira A.P., Murray C.S., Simpson A.. Environmental Influences on Childhood Asthma: Allergens. Pediatr. Allergy Immunol.. 2023;34 e13915. doi:10.1111/pai.13915
71. Murrison L.B., Brandt E.B., Myers J.B., Hershey G.K.K.. Environmental Exposures and Mechanisms in Allergy and Asthma Development. J. Clin. Investig.. 2019;129 1504–1515. doi:10.1172/JCI124612
72. Singh S., Salvi S., Mangal D.K., Singh M., Awasthi S., Mahesh P.A., et al.. Prevalence, Time Trends and Treatment Practices of Asthma in India: The Global Asthma Network Study. ERJ Open. Res.. 2022;8 00528–02021. doi:10.1183/23120541.00528-2021
73. Kumar G., Roy G., Subitha L., Sahu S.. Prevalence of Bronchial Asthma and Its Associated Factors among School Children in Urban Puducherry, India. J. Nat. Sc. Biol. Med.. 2014;5 59. doi:10.4103/0976-9668.127289
74. López-Villarrubia E., Costa Estirado O., Íñiguez Hernández C., Ballester Díez F.. Do Saharan Dust Days Carry a Risk of Hospitalization From Respiratory Diseases for Citizens of the Canary Islands (Spain)?. Arch. Bronconeumol.. 2021;57 464–470. doi:10.1016/j.arbres.2020.03.009
75. Doganay H., Akcali D., Goktaş T., Caglar K., Erbas D., Saydam C., et al.. African Dust-Laden Atmospheric Conditions Activate the Trigeminovascular System. Cephalalgia. 2009;29 1059–1068. doi:10.1111/j.1468-2982.2008.01839.x
76. Haghdoost F., Togha M.. Migraine Management: Non-Pharmacological Points for Patients and Health Care Professionals. Open. Med.. 2022;17 1869–1882. doi:10.1515/med-2022-0598
77. Cady R.K., Schreiber C.P.. Sinus Headache: A Clinical Conundrum. Otolaryngol. Clin. N. Am.. 2004;37 267–288. doi:10.1016/S0030-6665(03)00181-6
78. Kim J.-H.. The Emerging Role of TRPV1 in Airway Inflammation. Allergy Asthma Immunol. Res.. 2018;10 187. doi:10.4168/aair.2018.10.3.187
79. Meents J.E., Neeb L., Reuter U.. TRPV1 in Migraine Pathophysiology. Trends Mol. Med.. 2010;16 153–159. doi:10.1016/j.molmed.2010.02.004
80. Sordyl J., Kopyta I., Sarecka-Hujar B., Matusik P., Francuz T., Malecka-Tendera E.. Selected Factors of Vascular Changes: The Potential Pathological Processes Underlying Primary Headaches in Children. Children. 2022;9 doi:10.3390/children9111660
81. Wang F., Cao Y., Liu Y., Ren Z., Li F.. Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis. Behav. Neurol.. 2022;2022 2118740. doi:10.1155/2022/2118740
82. Buyukyilmaz G., Soyer O.U., Buyuktiryaki B., Alioglu B., Dallar Y.. Platelet Aggregation, Secretion, and Coagulation Changes in Children with Asthma. Blood Coagul. Fibrinolysis. 2014;25 738–744. doi:10.1097/MBC.0000000000000136
83. Pavón-Romero G.F., Serrano-Pérez N.H., García-Sánchez L., Ramírez-Jiménez F., Terán L.M.. Neuroimmune Pathophysiology in Asthma. Front. Cell. Dev. Biol.. 2021;9 663535. doi:10.3389/fcell.2021.663535
84. Rahmann A., Wienecke T., Hansen J.M., Fahrenkrug J., Olesen J., Ashina M.. Vasoactive Intestinal Peptide Causes Marked Cephalic Vasodilation, but Does Not Induce Migraine. Cephalalgia. 2008;28 226–236. doi:10.1111/j.1468-2982.2007.01497.x
85. Kaleagasi H., Özgür E., Özge C., Özge A.. Bronchial Hyper-Reactivity in Migraine without Aura: Is It a New Clue for Inflammation?. Headache. 2011;51 426–431. doi:10.1111/j.1526-4610.2010.01798.x
86. Benemei S., De Cesaris F., Fusi C., Rossi E., Lupi C., Geppetti P.. TRPA1 and Other TRP Channels in Migraine. J. Headache Pain. 2013;14 71. doi:10.1186/1129-2377-14-71
87. Satia I., Nagashima A., Usmani O.S.. Exploring the Role of Nerves in Asthma; Insights from the Study of Cough. Biochemical Pharmacology. 2020;179 113901. doi:10.1016/j.bcp.2020.113901
88. Bellamy J.L., Cady R.K., Durham P.L.. Salivary Levels of CGRP and VIP in Rhinosinusitis and Migraine Patients. Headache. 2006;46 24–33. doi:10.1111/j.1526-4610.2006.00294.x
89. Galli S.J., Tsai M.. IgE and Mast Cells in Allergic Disease. Nat. Med.. 2012;18 693–704. doi:10.1038/nm.2755
90. Liccardi G., Salzillo A., Calzetta L., Cazzola M., Matera M.G., Rogliani P.. Can Bronchial Asthma with an Highly Prevalent Airway (and Systemic) Vagal Tone Be Considered an Independent Asthma Phenotype? Possible Role of Anticholinergics. Respir. Med.. 2016;117 150–153. doi:10.1016/j.rmed.2016.05.026
91. Shelukhina I., Mikhailov N., Abushik P., Nurullin L., Nikolsky E.E., Giniatullin R.. Cholinergic Nociceptive Mechanisms in Rat Meninges and Trigeminal Ganglia: Potential Implications for Migraine Pain. Front. Neurol.. 2017;8 163. doi:10.3389/fneur.2017.00163
92. Haas H.L., Sergeeva O.A., Selbach O.. Histamine in the Nervous System. Physiol. Rev.. 2008;88 1183–1241. doi:10.1152/physrev.00043.2007
93. Philippu A., Prast H.. Importance of Histamine in Modulatory Processes, Locomotion and Memory. Behav. Brain Res.. 2001;124 151–159. doi:10.1016/S0166-4328(01)00226-1
94. Nuutinen S., Panula P.. Histamine in Neurotransmission and Brain Diseases. Adv. Exp. Med. Biol.. 2010;709 95–107. doi:10.1007/978-1-4419-8056-4_10
95. Olesen J., Thomsen L.L., Lassen L.H., Olesen I.J.. The Nitric Oxide Hypothesis of Migraine and Other Vascular Headaches. Cephalalgia. 1995;15 94–100. doi:10.1046/j.1468-2982.1995.015002094.x
96. Hough L.B., Rice F.L.. H3 Receptors and Pain Modulation: Peripheral, Spinal, and Brain Interactions. J. Pharmacol. Exp. Ther.. 2011;336 30–37. doi:10.1124/jpet.110.171264
97. Leurs R., Bakker R.A., Timmerman H., de Esch I.J.P.. The Histamine H3 Receptor: From Gene Cloning to H3 Receptor Drugs. Nat. Rev. Drug. Discov.. 2005;4 107–120. doi:10.1038/nrd1631
98. Cannon K.E., Nalwalk J.W., Stadel R., Ge P., Lawson D., Silos-Santiago I., et al.. Activation of Spinal Histamine H3 Receptors Inhibits Mechanical Nociception. Eur. J. Pharmacol.. 2003;470 139–147. doi:10.1016/S0014-2999(03)01737-0
99. Ottosson A., Edvinsson L.. Release of Histamine from Dural Mast Cells by Substance P and Calcitonin Gene-Related Peptide. Cephalalgia. 1997;17 166–174. doi:10.1046/j.1468-2982.1997.1703166.x
100. Yuan H., Silberstein S.D.. Histamine and Migraine. Headache. 2018;58 184–193. doi:10.1111/head.13164
101. Millichap J.G., Yee M.M.. The Diet Factor in Pediatric and Adolescent Migraine. Pediatr. Neurol.. 2003;28 9–15. doi:10.1016/S0887-8994(02)00466-6
102. Krymchantowski A.V., da Cunha Jevoux C.. Wine and Headache. Headache. 2014;54 967–975. doi:10.1111/head.12365
103. Krabbe A.A., Olesen J.. Headache Provocation by Continuous Intravenous Infusion of Histamine. Clinical Results and Receptor Mechanisms. Pain. 1980;8 253–259. doi:10.1016/0304-3959(88)90012-7
104. Heatley R.V., Denburg J.A., Bayer N., Bienenstock J.. Increased Plasma Histamine Levels in Migraine Patients. Clin. Allergy. 1982;12 145–149. doi:10.1111/j.1365-2222.1982.tb01633.x
105. Cote N.K., Harrington M.E.. Histamine Phase Shifts the Circadian Clock in a Manner Similar to Light. Brain Res.. 1993;613 149–151. doi:10.1016/0006-8993(93)90465-Y
106. Jacobs E.H., Yamatodani A., Timmerman H.. Is Histamine the Final Neurotransmitter in the Entrainment of Circadian Rhythms in Mammals?. Trends Pharmacol. Sci.. 2000;21 293–298. doi:10.1016/S0165-6147(00)01504-2
107. Tabarean I.V.. Histamine Receptor Signaling in Energy Homeostasis. Neuropharmacology. 2016;106 13–19. doi:10.1016/j.neuropharm.2015.04.011
108. Lin J.-S., Anaclet C., Sergeeva O.A., Haas H.L.. The Waking Brain: An Update. Cell. Mol. Life Sci.. 2011;68 2499–2512. doi:10.1007/s00018-011-0631-8
109. Ferini-Strambi L., Galbiati A., Combi R.. Sleep Disorder-Related Headaches. Neurol. Sci.. 2019;40 107–113. doi:10.1007/s10072-019-03837-z
110. Van Oosterhout F., Michel S., Deboer T., Houben T., van de Ven R.C.G., Albus H., et al.. Enhanced Circadian Phase Resetting in R192Q Cav2.1 Calcium Channel Migraine Mice. Ann. Neurol.. 2008;64 315–324. doi:10.1002/ana.21418
111. Obara I., Telezhkin V., Alrashdi I., Chazot P.L.. Histamine, Histamine Receptors, and Neuropathic Pain Relief. Br. J. Pharmacol.. 2020;177 580–599. doi:10.1111/bph.14696
112. Kagan R., Kainz V., Burstein R., Noseda R.. Hypothalamic and Basal Ganglia Projections to the Posterior Thalamus: Possible Role in Modulation of Migraine Headache and Photophobia. Neuroscience. 2013;248 359–368. doi:10.1016/j.neuroscience.2013.06.014
113. Ohkubo T., Shibata M., Inoue M., Kaya H., Takahashi H.. Regulation of Substance P Release Mediated via Prejunctional Histamine H3 Receptors. Eur. J. Pharmacol.. 1995;273 83–88. doi:10.1016/0014-2999(94)00668-W
114. Akerman S., Holland P.R., Goadsby P.J.. Diencephalic and Brainstem Mechanisms in Migraine. Nat. Rev. Neurosci.. 2011;12 570–584. doi:10.1038/nrn3057
115. Roberts F., Calcutt C.R.. Histamine and the Hypothalamus. Neuroscience. 1983;9 721–739. doi:10.1016/0306-4522(83)90264-6
116. Kursun O., Yemisci M., van den Maagdenberg A.M.J.M., Karatas H.. Migraine and Neuroinflammation: The Inflammasome Perspective. J. Headache Pain. 2021;22 55. doi:10.1186/s10194-021-01271-1
117. Westerink B.H.C., Cremers T.I.F.H., De Vries J.B., Liefers H., Tran N., De Boer P.. Evidence for Activation of Histamine H3 Autoreceptors during Handling Stress in the Prefrontal Cortex of the Rat. Synapse. 2002;43 238–243. doi:10.1002/syn.10043
118. Mochizuki T.. Histamine as an Alert Signal in the Brain. Curr. Top. Behav. Neurosci.. 2022;59 413–425. doi:10.1007/7854_2021_249
119. Maintz L., Novak N.. Histamine and Histamine Intolerance. Am. J. Clin. Nutr.. 2007;85 1185–1196. doi:10.1093/ajcn/85.5.1185
120. De Marchis M.L., Guadagni F., Silvestris E., Lovero D., Della-Morte D., Ferroni P., et al.. Genetic Bases of the Nutritional Approach to Migraine. Crit. Rev. Food Sci. Nutr.. 2019;59 2308–2320. doi:10.1080/10408398.2018.1450215
121. Abbott N.J., Rönnbäck L., Hansson E.. Astrocyte-Endothelial Interactions at the Blood-Brain Barrier. Nat. Rev. Neurosci.. 2006;7 41–53. doi:10.1038/nrn1824
122. Haas H., Panula P.. The Role of Histamine and the Tuberomamillary Nucleus in the Nervous System. Nat. Rev. Neurosci.. 2003;4 121–130. doi:10.1038/nrn1034
123. Michinaga S., Sonoda K., Inazuki N., Ezaki M., Awane H., Shimizu K., et al.. Selective Histamine H2 Receptor Agonists Alleviate Blood-Brain Barrier Disruption by Promoting the Expression of Vascular Protective Factors Following Traumatic Brain Injury in Mice. J. Pharmacol. Sci.. 2022;150 135–145. doi:10.1016/j.jphs.2022.08.003
124. Flores-Clemente C., Osorio-Espinoza A., Escamilla-Sánchez J., Leurs R., Arias J.-M., Arias-Montaño J.-A.. A Single-Point Mutation (Ala280Val) in the Third Intracellular Loop Alters the Signalling Properties of the Human Histamine H₃ Receptor Stably Expressed in CHO-K1 Cells. Br. J. Pharmacol.. 2013;170 127–135. doi:10.1111/bph.12257
125. Millán-Guerrero R.O., Baltazar-Rodríguez L.M., Cárdenas-Rojas M.I., Ramírez-Flores M., Isais-Millán S., Delgado-Enciso I., et al.. A280V Polymorphism in the Histamine H3 Receptor as a Risk Factor for Migraine. Arch. Med. Res.. 2011;42 44–47. doi:10.1016/j.arcmed.2011.01.009
126. Millán-Guerrero R.O., Isais-Millán R., Barreto-Vizcaíno S., Rivera-Castaño L., Garcia-Solorzano A., López-Blanca C., et al.. Subcutaneous Histamine versus Sodium Valproate in Migraine Prophylaxis: A Randomized, Controlled, Double-Blind Study. Eur. J. Neurol.. 2007;14 1079–1084. doi:10.1111/j.1468-1331.2007.01744.x
127. McLeod R.L., Aslanian R., del Prado M., Duffy R., Egan R.W., Kreutner W., et al.. Sch 50971, an Orally Active Histamine H3 Receptor Agonist, Inhibits Central Neurogenic Vascular Inflammation and Produces Sedation in the Guinea Pig. J. Pharmacol. Exp. Ther.. 1998;287 43–50.
128. Strakhova M.I., Nikkel A.L., Manelli A.M., Hsieh G.C., Esbenshade T.A., Brioni J.D., et al.. Localization of Histamine H4 Receptors in the Central Nervous System of Human and Rat. Brain Res.. 2009;1250 41–48. doi:10.1016/j.brainres.2008.11.018
129. Galeotti N., Sanna M.D., Ghelardini C.. Pleiotropic Effect of Histamine H4 Receptor Modulation in the Central Nervous System. Neuropharmacology. 2013;71 141–147. doi:10.1016/j.neuropharm.2013.03.026
130. Nieto-Alamilla G., Márquez-Gómez R., García-Gálvez A.-M., Morales-Figueroa G.-E., Arias-Montaño J.-A.. The Histamine H3 Receptor: Structure, Pharmacology, and Function. Mol. Pharmacol.. 2016;90 649–673. doi:10.1124/mol.116.104752
131. Ramachandran R.. Neurogenic Inflammation and Its Role in Migraine. Semin. Immunopathol.. 2018;40 301–314. doi:10.1007/s00281-018-0676-y
132. Rosa A.C., Fantozzi R.. The Role of Histamine in Neurogenic Inflammation. Br. J. Pharmacol.. 2013;170 38–45. doi:10.1111/bph.12266
133. Levy D., Burstein R., Kainz V., Jakubowski M., Strassman A.M.. Mast Cell Degranulation Activates a Pain Pathway Underlying Migraine Headache. Pain. 2007;130 166–176. doi:10.1016/j.pain.2007.03.012
134. Conti P., D’Ovidio C., Conti C., Gallenga C.E., Lauritano D., Caraffa A., et al.. Progression in Migraine: Role of Mast Cells and pro-Inflammatory and Anti-Inflammatory Cytokines. Eur. J. Pharmacol.. 2019;844 87–94. doi:10.1016/j.ejphar.2018.12.004
135. Rao R., Hershey A.D.. An Update on Acute and Preventive Treatments for Migraine in Children and Adolescents. Expert. Rev. Neurother.. 2020;20 1017–1027. doi:10.1080/14737175.2020.1797493
136. Parikh S.K., Silberstein S.D.. Preventive Treatment for Episodic Migraine. Neurol. Clin.. 2019;37 753–770. doi:10.1016/j.ncl.2019.07.004
137. Papetti L., Ursitti F., Moavero R., Ferilli M.A.N., Sforza G., Tarantino S., et al.. Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?. Front. Neurol.. 2019;10 771. doi:10.3389/fneur.2019.00771
138. Papetti L., Moavero R., Ferilli M.A.N., Sforza G., Tarantino S., Ursitti F., et al.. Truths and Myths in Pediatric Migraine and Nutrition. Nutrients. 2021;13 doi:10.3390/nu13082714
139. Kelley N.E., Tepper D.E.. Rescue Therapy for Acute Migraine, Part 2: Neuroleptics, Antihistamines, and Others. Headache. 2012;52 292–306. doi:10.1111/j.1526-4610.2011.02070.x
140. Worm J., Falkenberg K., Olesen J.. Histamine and Migraine Revisited: Mechanisms and Possible Drug Targets. J. Headache Pain. 2019;20 30. doi:10.1186/s10194-019-0984-1
141. Curran D.A., Lance J.W.. Clinical Trial Of Methysergide And Other Preparations In The Management Of Migraine. J. Neurol. Neurosurg. Psychiatry. 1964;27 463–469. doi:10.1136/jnnp.27.5.463
142. Tek D., Mellon M.. The Effectiveness of Nalbuphine and Hydroxyzine for the Emergency Treatment of Severe Headache. Ann. Emerg. Med.. 1987;16 308–313. doi:10.1016/S0196-0644(87)80177-4
143. Rossi P., Fiermonte G., Pierelli F.. Cinnarizine in Migraine Prophylaxis: Efficacy, Tolerability and Predictive Factors for Therapeutic Responsiveness. An Open-Label Pilot Trial. Funct. Neurol.. 2003;18 155–159.
144. Bostani A., Rajabi A., Moradian N., Razazian N., Rezaei M.. The Effects of Cinnarizine versus Sodium Valproate in Migraine Prophylaxis. Int. J. Neurosci.. 2013;123 487–493. doi:10.3109/00207454.2013.765419
145. Ashrafi M.R., Salehi S., Malamiri R.A., Heidari M., Hosseini S.A., Samiei M., et al.. Efficacy and Safety of Cinnarizine in the Prophylaxis of Migraine in Children: A Double-Blind Placebo-Controlled Randomized Trial. Pediatr. Neurol.. 2014;51 503–508. doi:10.1016/j.pediatrneurol.2014.05.031
146. Amanat M., Togha M., Agah E., Ramezani M., Tavasoli A.R., Azizi Malamiri R., et al.. Cinnarizine and Sodium Valproate as the Preventive Agents of Pediatric Migraine: A Randomized Double-Blind Placebo-Controlled Trial. Cephalalgia. 2020;40 665–674. doi:10.1177/0333102419888485
147. Vollesen L.H., Guo S., Andersen M.R., Ashina M.. Effect of the H1-Antihistamine Clemastine on PACAP38 Induced Migraine. Cephalalgia. 2019;39 597–607. doi:10.1177/0333102418798611
148. Anthony M., Lord G.D., Lance J.W.. Controlled Trials of Cimetidine in Migraine and Cluster Headache. Headache. 1978;18 261–264. doi:10.1111/j.1526-4610.1978.hed1805261.x
149. Nanda R.N., Arthur G.P., Johnson R.H., Lambie D.G.. Cimetidine in the Prophylaxis of Migraine. Acta Neurol. Scand.. 1980;62 90–95. doi:10.1111/j.1600-0404.1980.tb03008.x
150. Millán-Guerrero R.O., Pineda-Lucatero A.G., Hernández-Benjamín T., Tene C.E., Pacheco M.F.. Nalpha-Methylhistamine Safety and Efficacy in Migraine Prophylaxis: Phase I and Phase II Studies. Headache. 2003;43 389–394. doi:10.1046/j.1526-4610.2003.03074.x
151. Millán-Guerrero R.O., Isais-Millán R., Barreto-Vizcaíno S., Gutiérrez I., Rivera-Castaño L., Trujillo-Hernández B., et al.. Subcutaneous Histamine versus Topiramate in Migraine Prophylaxis: A Double-Blind Study. Eur. Neurol.. 2008;59 237–242. doi:10.1159/000115637
152. Millán-Guerrero R.O., Isais-Millán S., Barreto-Vizcaíno S., Rivera-Castaño L., Rios-Madariaga C.. Subcutaneous Histamine versus Botulinum Toxin Type A in Migraine Prophylaxis: A Randomized, Double-Blind Study. Eur. J. Neurol.. 2009;16 88–94. doi:10.1111/j.1468-1331.2008.02352.x
153. Millán-Guerrero R.O., Isais-Millán R., Guzmán-Chávez B., Castillo-Varela G.. N Alpha Methyl Histamine versus Propranolol in Migraine Prophylaxis. Can. J. Neurol. Sci.. 2014;41 233–238. doi:10.1017/S0317167100016632
154. Hsieh G.C., Chandran P., Salyers A.K., Pai M., Zhu C.Z., Wensink E.J., et al.. H4 Receptor Antagonism Exhibits Anti-Nociceptive Effects in Inflammatory and Neuropathic Pain Models in Rats. Pharmacol. Biochem. Behav.. 2010;95 41–50. doi:10.1016/j.pbb.2009.12.004
155. Coruzzi G., Adami M., Guaita E., de Esch I.J.P., Leurs R.. Antiinflammatory and Antinociceptive Effects of the Selective Histamine H4-Receptor Antagonists JNJ7777120 and VUF6002 in a Rat Model of Carrageenan-Induced Acute Inflammation. Eur. J. Pharmacol.. 2007;563 240–244. doi:10.1016/j.ejphar.2007.02.026
156. Millán-Guerrero R.O., Isais-Millán R., Benjamín T.-H., Tene C.E.. Nalpha-Methyl Histamine Safety and Efficacy in Migraine Prophylaxis: Phase III Study. Can. J. Neurol. Sci.. 2006;33 195–199. doi:10.1017/S0317167100004960
157. Rao B.S., Das D.G., Taraknath V.R., Sarma Y.. A Double Blind Controlled Study of Propranolol and Cyproheptadine in Migraine Prophylaxis. Neurol. India. 2000;48 223–226.
158. Al-Majed A.A., Bakheit A.H.H., Abdel Aziz H.A., Alajmi F.M., AlRabiah H.. Propranolol. Profiles Drug. Subst. Excip. Relat. Methodol.. 2017;42 287–338. doi:10.1016/bs.podrm.2017.02.006
159. Fumagalli C., Maurizi N., Marchionni N., Fornasari D.. β-Blockers: Their New Life from Hypertension to Cancer and Migraine. Pharmacol. Res.. 2020;151 104587. doi:10.1016/j.phrs.2019.104587
160. Silberstein S.D.. Preventive Migraine Treatment. Continuum. 2015;21 973–989. doi:10.1212/CON.0000000000000199
161. Holmes B., Brogden R.N., Heel R.C., Speight T.M., Avery G.S.. Flunarizine. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use. Drugs. 1984;27 6–44. doi:10.2165/00003495-198427010-00002
162. Van Nueten J.M., Janssens W.J.. Cerebral Antivasoconstrictive Effects of Flunarizine. Acta Otolaryngol. Suppl.. 1988;460 42–49. doi:10.3109/00016488809125134
163. Stubberud A., Flaaen N.M., McCrory D.C., Pedersen S.A., Linde M.. Flunarizine as Prophylaxis for Episodic Migraine: A Systematic Review with Meta-Analysis. Pain. 2019;160 762–772. doi:10.1097/j.pain.0000000000001456
164. Liu F., Ma T., Che X., Wang Q., Yu S.. The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine. Front. Neurol.. 2017;8 524. doi:10.3389/fneur.2017.00524
165. Silberstein S.D.. Methysergide. Cephalalgia. 1998;18 421–435. doi:10.1046/j.1468-2982.1998.1807421.x
166. Loprinzi C.L., Stearns V., Barton D.. Centrally Active Nonhormonal Hot Flash Therapies. Am. J. Med.. 2005;118 118–123. doi:10.1016/j.amjmed.2005.09.045
167. Togha M., Martami F., Abdollahi M., Mozafari M., Cheraghali H., Rafiee P., et al.. Cinnarizine as an Alternative Recommendation for Migraine Prophylaxis: A Narrative Review. Expert Rev. Neurother.. 2020;20 943–951. doi:10.1080/14737175.2020.1787834
168. Shafie’ei M., Kouhanjani M.F., Akbari Z., Sarvipour N., Shekouh D., Gholampour M., et al.. Application of Cinnarizine in Migraine Prevention: A Systematic Review and Meta-Analysis. Pain Pract.. 2022;22 733–745. doi:10.1111/papr.13164
169. Díaz N.F., Flores-Herrera H., García-López G., Molina-Hernández A.. Central Histamine, the H3-Receptor and Obesity Therapy. CNS Neurol. Disord. Drug. Targets. 2019;18 516–522. doi:10.2174/1871527318666190703094846
170. Szczepańska K., Podlewska S., Dichiara M., Gentile D., Patamia V., Rosier N., et al.. Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties. ACS Chem. Neurosci.. 2022;13 1–15. doi:10.1021/acschemneuro.1c00435
171. West R.E., Zweig A., Shih N.Y., Siegel M.I., Egan R.W., Clark M.A.. Identification of Two H3-Histamine Receptor Subtypes. Mol. Pharmacol.. 1990;38 610–613.
172. Arrang J.M., Garbarg M., Schwartz J.C.. Autoinhibition of Histamine Synthesis Mediated by Presynaptic H3-Receptors. Neuroscience. 1987;23 149–157. doi:10.1016/0306-4522(87)90279-X
173. Lampl C., Versijpt J., Amin F.M., Deligianni C.I., Gil-Gouveia R., Jassal T., et al.. European Headache Federation (EHF) Critical Re-Appraisal and Meta-Analysis of Oral Drugs in Migraine Prevention-Part 1: Amitriptyline. J. Headache Pain. 2023;24 39. doi:10.1186/s10194-023-01573-6
174. Connelly W.M., Shenton F.C., Lethbridge N., Leurs R., Waldvogel H.J., Faull R.L.M., et al.. The Histamine H4 Receptor Is Functionally Expressed on Neurons in the Mammalian CNS. Br. J. Pharmacol.. 2009;157 55–63. doi:10.1111/j.1476-5381.2009.00227.x
175. Edginton S., O’Sullivan D.E., King W.D., Lougheed M.D.. The Effect of Acute Outdoor Air Pollution on Peak Expiratory Flow in Individuals with Asthma: A Systematic Review and Meta-Analysis. Environ. Res.. 2021;192 110296. doi:10.1016/j.envres.2020.110296
176. Lee H., Myung W., Cheong H.-K., Yi S.-M., Hong Y.-C., Cho S.-I., et al.. Ambient Air Pollution Exposure and Risk of Migraine: Synergistic Effect with High Temperature. Environ. Int.. 2018;121 383–391. doi:10.1016/j.envint.2018.09.022

Where this page came from

This page was imported from Journal of Clinical Medicine (PubMed Central). “Migraine, Allergy, and Histamine: Is There a Link?” by Alessandro Ferretti, Mattia Gatto, Margherita Velardi et al., Journal of Clinical Medicine (2023), doi:10.3390/jcm12103566, published under CC BY 4.0. Changed here: set as a page from the journal’s XML, its supplementary files left out; figures the article marks as reproduced under other terms are left out.

Nobody has written it yet — it is the source material at a new address, which is why search engines are asked to skip it and why no one earns from it. It is up for grabs: take it on, and it is yours to rewrite and to earn from.